Wilson Phung

Wilson Phung

Auto-generated profile, based on publicly available information

Wilson Phung

Department of Microchemistry, Proteomics and Lipidomics, Genentech, South San Francisco, CA, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2019 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
CHClémence Hollande
Clémence Hollande
JBJeremy Boussier
Jeremy Boussier
JZJames Ziai
James Ziai
TNTamaki Nozawa
Tamaki Nozawa
VBVincent Bondet
Vincent Bondet
MAMatthew L. Albert
Matthew L. Albert

27 January 2020 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
PDF file
NLNicholas Liau
Nicholas Liau
TWTimothy J. Wendorff
Timothy J. Wendorff
JQJohn G. Quinn
John G. Quinn
MSMicah Steffek
Micah Steffek
WPWilson Phung
Wilson Phung
JSJawahar Sudhamsu
Jawahar Sudhamsu

18 September 2019 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
NZNathan W. Zammit
Nathan W. Zammit
OSOwen M Siggs
Owen M Siggs
PGPaul E. Gray
Paul E. Gray
KHKeisuke Horikawa
Keisuke Horikawa
DLDavid B. Langley
David B. Langley
SGShane T. Grey
Shane T. Grey

1 January 2021 in mAbs
Verified
Journal Article
Open access
BWBingchuan Wei
Bingchuan Wei
XGXuan Gao
Xuan Gao
LCLance Janssen Cadang
Lance Janssen Cadang
SISaeed Izadi
Saeed Izadi
PLPeilu Liu
Peilu Liu
GJGuoying Jiang
Guoying Jiang
Fc galactosylation is a critical quality attribute for anti-tumor recombinant immunoglobulin G (IgG)-based monoclonal antibody (mAb) therapeutics with complement-dependent cytotoxicity (CDC) as the mechanism of action. Although the correlation between galactosylation and CDC has been known, the underlying structure–function relationship is unclear. Heterogeneity of the Fc N-glycosylation produced by Chinese hamster ovary (CHO) cell culture biomanufacturing process leads to variable CDC potency. Here, we derived a kinetic model of galactose transfer reaction in the Golgi apparatus and used this model to determine the correlation between differently galactosylated species from CHO cell culture process. The model was validated by a retrospective data analysis of more than 800 historical samples from small-scale and large-scale CHO cell cultures. Furthermore, using various analytical technologies, we discovered the molecular basis for Fc glycan terminal galactosylation changing the three-dimensional conformation of the Fc, which facilitates the IgG1 hexamerization, thus enhancing C1q avidity and subsequent complement activation. Our study offers insight into the formation of galactosylated species, as well as a novel three-dimensional understanding of the structure–function relationship of terminal galactose to complement activation in mAb therapeutics.

21 March 2022 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
RSRosa Barreira da Silva
Rosa Barreira da Silva
RLRicardo M. Leitao
Ricardo M. Leitao
XPXimo Pechuan-Jorge
Ximo Pechuan-Jorge
SWScott Werneke
Scott Werneke
JOJason Oeh
Jason Oeh
MAMatthew L. Albert
Matthew L. Albert

24 September 2020 in Biochemistry
Verified
Journal Article
Closed access
NLNicholas Liau
Nicholas Liau
AVAvinashnarayan Venkatanarayan
Avinashnarayan Venkatanarayan
JQJohn G. Quinn
John G. Quinn
WPWilson Phung
Wilson Phung
SMShiva Malek
Shiva Malek
JSJawahar Sudhamsu
Jawahar Sudhamsu